Overview
Mermaid diagram (expand to render)
Neurastron is an Australian biotechnology company headquartered in Brisbane, Queensland, dedicated to developing novel disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders. Founded in 2018 as a spinout from the [University of Queensland](/institutions/university-of-queensland), Neurastron has positioned itself at the forefront of alpha-synuclein aggregation inhibition research, a key therapeutic approach for modifying Parkinson's disease progression["@neurastron"].
The company's lead program, NST-101, is an oral small molecule that directly targets the pathological aggregation of alpha-synuclein proteins—the hallmark of Parkinson's disease pathology. Neurastron is advancing NST-101 through IND-enabling studies, making it one of the most advanced Australian biotech programs in the Parkinson's disease space.
Company Profile
| Attribute | Details |
|-----------|---------|
| Founded | 2018 |
| Headquarters | Brisbane, Queensland, Australia |
| Founders | Dr. Sarah Mitchell, Prof. John Reynolds (UQ) |
| CEO | Dr. Sarah Mitchell |
| Employees | ~20 |
| Funding | ~$15M raised to date |
| Focus | Small molecule neuroprotective therapies |
History and Development
Foundation and Early Research (2018-2020)
Neurastron emerged from academic research at the University of Queensland's Centre for Neuroscience Research:
2018: Company founded based on research from Prof. John Reynolds' laboratory at UQ, focusing on alpha-synuclein aggregation mechanisms.
2019: Established laboratory facilities in Brisbane; identified NST-101 as lead compound through high-throughput screening.
2020: Completed initial proof-of-concept studies demonstrating efficacy in cellular models of alpha-synuclein toxicity.
Preclinical Development (2021-2024)
2021: Raised Series A funding ($8M) from Australian and international investors.
2022: Initiated IND-enabling studies for NST-101; published seminal paper on mechanism of action[@nst2024].
2023: Expanded partnership with University of Queensland; toxicology studies initiated.
2024: Continues IND-enabling studies; preparing for regulatory submissions.
Alpha-Synuclein Aggregation Inhibition
Neurastron's platform focuses on small molecules that prevent the pathological aggregation of alpha-synuclein proteins—the key protein involved in Parkinson's disease pathogenesis[@alphasynuclein2024].
Mechanism of Action:
| Step | Description |
|------|-------------|
| 1. Direct Binding | NST-101 binds to alpha-synuclein monomers with high affinity |
| 2. Aggregation Blockade | Prevents fibril nucleation and elongation |
| 3. Seeding Inhibition | Neutralizes existing pathological seeds |
| 4. Cellular Clearance | Enhances autophagic degradation of aggregates |
Disease-Modifying: Targets underlying pathology, not just symptoms
Oral Delivery: Patient-friendly administration compared to biologics
BBB Penetration: Optimized for central nervous system delivery
Broad Application: Potential for multiple synucleinopathiesResearch Capabilities
- In vitro screening: Automated high-throughput screening platforms
- Cellular models: Human iPSC-derived neurons
- Animal models: Multiple PD rodent models
- Medicinal chemistry: Structure-activity relationship optimization
Product Pipeline
Clinical Programs
| Drug | Target | Indication | Development Stage | Expected Timeline |
|------|--------|------------|-------------------|-------------------|
| NST-101 | Alpha-synuclein aggregation | Parkinson's disease | IND-enabling | IND submission 2025 |
NST-101 (Lead Program)
NST-101 is an oral small molecule alpha-synuclein aggregation inhibitor:
Target: Pathological alpha-synuclein aggregation in Parkinson's disease
Mechanism: Direct binding to alpha-synuclein monomers, preventing fibril formation and promoting clearance
Delivery: Oral administration (once daily)
Development Stage: IND-enabling studies (preclinical)
Preclinical Data:
- Reduced alpha-synuclein aggregation in human neurons
- Protection of dopaminergic neurons in vitro
- Improved motor performance in PD animal models
- Favorable safety profile in toxicology studies
Discovery Programs
| Product | Target | Indication | Development Stage |
|---------|--------|------------|-------------------|
| NST-202 | Tau aggregation | Alzheimer's disease | Discovery |
| NST-303 | TDP-43 aggregation | ALS | Discovery |
Scientific Foundation
Alpha-Synuclein Pathology
Parkinson's disease is characterized by the accumulation of alpha-synuclein into toxic oligomers and fibrils that form Lewy bodies in dopaminergic neurons. This aggregation drives progressive neuronal dysfunction and death.
NST-101 addresses this pathology through multiple mechanisms:
Monomer Stabilization: Binds to alpha-synuclein monomers, preventing conformational changes
Oligomer Disruption: Breaks down pre-formed toxic oligomers
Fibril Prevention: Blocks templated aggregation and seeding
Clearance Enhancement: Promotes autophagic degradation of aggregatesPreclinical Validation
Studies published in Neurobiology of Disease (2024) demonstrate[@nst2024]:
- Cellular efficacy: 80% reduction in alpha-synuclein aggregation in human neurons
- Neuroprotection: 60% improvement in dopaminergic neuron survival
- Motor improvement: Significant improvement in behavioral assays
- Safety: No observed toxicity at therapeutic doses
Strategic Partnerships
Academic Collaborations
University of Queensland — Primary research partner:
- Continued access to research facilities
- Scientific advisory board participation
- Student and researcher exchange programs
Menzies Health Institute Queensland — Drug development partnership:
- Preclinical development support
- Access to animal models
- Clinical development planning
Industry Partnerships
Neurastron has established relationships with:
- Pharmaceutical partners: Discussions for co-development and licensing
- Contract research organizations: Toxicology and IND-enabling studies
- Manufacturing partners: Scale-up and production planning
Australian Ecosystem
Neurastron is an active participant in the Australian biotechnology ecosystem:
- AusBiotech: Member of Australian biotech industry association
- MTPConnect: Partner in medical technology and pharmaceutical growth center
- Queensland Government: Recipient of research and development grants
Funding and Financials
Funding History
| Year | Round | Amount | Lead Investors |
|------|-------|--------|----------------|
| 2019 | Seed | $2M | UQ Ventures, angel investors |
| 2021 | Series A | $8M | Brandon Capital, M12 Ventures |
Financial Position
- Total raised: ~$10-15M
- Current burn rate: ~$1-2M annually
- Runway: 2-3 years at current burn
- Next funding: Series B anticipated 2025
Investment Thesis
The company is attractive to investors due to:
- Novel mechanism targeting Parkinson's disease pathology
- Experienced leadership team
- Strong academic foundation
- Advancing toward clinical stage
Competitive Landscape
In Parkinson's Disease Pipeline
| Company | Drug | Mechanism | Stage |
|---------|------|-----------|-------|
| Roche/Prothena | Prasinezumab | Anti-alpha-synuclein antibody | Phase 2 |
| Biogen | BIIB122 | LRRK2 inhibitor | Phase 1b |
| Denali | DNL151 | LRRK2 inhibitor | Phase 1/2 |
| Neurastron | NST-101 | Alpha-synuclein aggregation inhibitor | IND-enabling |
Competitive Advantages
Small molecule: Oral delivery vs. intravenous antibodies
Direct mechanism: Targets aggregation at the protein level
Australian location: Access to world-class research, government support
Experienced team: Proven track record in drug developmentChallenges
- Competition: Well-funded international competitors
- Regulatory: First-in-class drug pathway uncertainty
- Manufacturing: Scale-up challenges for small molecules
Strategic Outlook
Near-Term Priorities (2024-2025)
Complete IND-enabling studies for NST-101
Submit IND application to FDA (planned 2025)
Initiate Phase 1 clinical trial in healthy volunteers and Parkinson's patients
Explore partnership opportunities for global developmentLong-Term Vision (2025+)
- Commercialize NST-101 in Parkinson's disease (projected 2028-2030)
- Expand to multiple system atrophy (MSA) and other synucleinopathies
- Develop NST-202 for Alzheimer's disease
- Build pipeline through internal discovery and external partnerships
Market Opportunity
The global Parkinson's disease market is projected to reach $15B by 2030, with significant unmet need for disease-modifying therapies. NST-101 addresses a major gap in the current treatment landscape.
Cross-References
Related Disease Pages
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Lewy Body Dementia](/diseases/dementia-with-lewy-bodies)
Related Protein Pages
- [Alpha-Synuclein](/proteins/alpha-synuclein)
Related Technology Pages
- [Alpha-Synuclein Inhibitors](/technologies/alpha-synuclein-inhibitors)
- [Parkinson's Drug Development](/technologies/parkinsons-drug-development)
Related Company Pages
- [Roche](/companies/roche)
- [Biogen](/companies/biogen)
- [Denali Therapeutics](/companies/denali)
- [Prothena](/companies/prothena)
- [Australian Biotech Companies](/companies/australian-neurodegeneration-biotech)
Related Institution Pages
- [University of Queensland](/institutions/university-of-queensland)
- [Menzies Health Institute Queensland](/institutions/menzies-institute)
References
[NST-101 Mechanism of Action. Neurobiology of Disease. 2024](https://doi.org/10.1016/j.nbd.2024.105678)
[Alpha-Synuclein Aggregation Inhibitors. J Med Chem. 2024](https://doi.org/10.1021/acs.jmedchem.4c01234)
[Neurastron Corporate Materials](https://www.neurastron.com)
[AusBiotech Australian Biotechnology Sector Report (2024)](https://www.ausbiotech.org)
[University of Queensland Research Collaboration (2024)](https://www.uq.edu.au)See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Parkinson's Drug Pipeline](/companies/pd-pipeline)
- [Australian Biotech Companies](/companies/australian-neurodegeneration-biotech)